nodes	percent_of_prediction	percent_of_DWPC	metapath
Flavoxate—PDE7A—renal system—uterine cancer	0.0428	0.0678	CbGeAlD
Flavoxate—Hyperpyrexia—Medroxyprogesterone Acetate—uterine cancer	0.0404	0.129	CcSEcCtD
Flavoxate—PDE8A—myometrium—uterine cancer	0.0368	0.0583	CbGeAlD
Flavoxate—PDE7A—female reproductive system—uterine cancer	0.0342	0.0543	CbGeAlD
Flavoxate—PDE8B—uterine cervix—uterine cancer	0.0318	0.0504	CbGeAlD
Flavoxate—PDE8A—uterine cervix—uterine cancer	0.0286	0.0454	CbGeAlD
Flavoxate—PDE8A—smooth muscle tissue—uterine cancer	0.0278	0.0441	CbGeAlD
Flavoxate—PDE8A—decidua—uterine cancer	0.0273	0.0432	CbGeAlD
Flavoxate—PDE8B—uterus—uterine cancer	0.0265	0.042	CbGeAlD
Flavoxate—PDE8A—endometrium—uterine cancer	0.0259	0.041	CbGeAlD
Flavoxate—PDE8A—mammalian vulva—uterine cancer	0.025	0.0397	CbGeAlD
Flavoxate—Raloxifene—ESR2—uterine cancer	0.0239	0.438	CrCbGaD
Flavoxate—PDE8A—uterus—uterine cancer	0.0239	0.0378	CbGeAlD
Flavoxate—PDE8B—female reproductive system—uterine cancer	0.0238	0.0378	CbGeAlD
Flavoxate—PDE4A—decidua—uterine cancer	0.0219	0.0347	CbGeAlD
Flavoxate—PDE8B—vagina—uterine cancer	0.0216	0.0342	CbGeAlD
Flavoxate—PDE8A—female gonad—uterine cancer	0.0195	0.0309	CbGeAlD
Flavoxate—PDE8A—vagina—uterine cancer	0.0194	0.0307	CbGeAlD
Flavoxate—PDE4D—female gonad—uterine cancer	0.0177	0.028	CbGeAlD
Flavoxate—PDE7B—lymph node—uterine cancer	0.0175	0.0278	CbGeAlD
Flavoxate—Raloxifene—CYP19A1—uterine cancer	0.016	0.293	CrCbGaD
Flavoxate—PDE4A—female gonad—uterine cancer	0.0156	0.0248	CbGeAlD
Flavoxate—Raloxifene—ESR1—uterine cancer	0.0147	0.27	CrCbGaD
Flavoxate—PDE8B—lymph node—uterine cancer	0.0139	0.0221	CbGeAlD
Flavoxate—PDE4B—uterine cervix—uterine cancer	0.0137	0.0217	CbGeAlD
Flavoxate—PDE4B—decidua—uterine cancer	0.013	0.0207	CbGeAlD
Flavoxate—PDE8A—lymph node—uterine cancer	0.0125	0.0199	CbGeAlD
Flavoxate—PDE4B—endometrium—uterine cancer	0.0124	0.0196	CbGeAlD
Flavoxate—PDE4B—mammalian vulva—uterine cancer	0.012	0.019	CbGeAlD
Flavoxate—PDE4D—lymph node—uterine cancer	0.0114	0.018	CbGeAlD
Flavoxate—PDE4B—female reproductive system—uterine cancer	0.0103	0.0163	CbGeAlD
Flavoxate—PDE4A—lymph node—uterine cancer	0.0101	0.0159	CbGeAlD
Flavoxate—PDE4B—female gonad—uterine cancer	0.00933	0.0148	CbGeAlD
Flavoxate—Drowsiness—Progesterone—uterine cancer	0.00928	0.0297	CcSEcCtD
Flavoxate—PDE4B—vagina—uterine cancer	0.00927	0.0147	CbGeAlD
Flavoxate—CHRM1—female reproductive system—uterine cancer	0.00927	0.0147	CbGeAlD
Flavoxate—Drowsiness—Medroxyprogesterone Acetate—uterine cancer	0.00841	0.0269	CcSEcCtD
Flavoxate—Tension—Progesterone—uterine cancer	0.00712	0.0227	CcSEcCtD
Flavoxate—Nervousness—Progesterone—uterine cancer	0.00705	0.0225	CcSEcCtD
Flavoxate—Vision blurred—Progesterone—uterine cancer	0.00684	0.0218	CcSEcCtD
Flavoxate—Vertigo—Progesterone—uterine cancer	0.00652	0.0208	CcSEcCtD
Flavoxate—Tension—Medroxyprogesterone Acetate—uterine cancer	0.00645	0.0206	CcSEcCtD
Flavoxate—Palpitations—Progesterone—uterine cancer	0.00641	0.0205	CcSEcCtD
Flavoxate—Nervousness—Medroxyprogesterone Acetate—uterine cancer	0.00638	0.0204	CcSEcCtD
Flavoxate—Dry mouth—Progesterone—uterine cancer	0.00604	0.0193	CcSEcCtD
Flavoxate—PDE4B—lymph node—uterine cancer	0.006	0.00951	CbGeAlD
Flavoxate—Confusional state—Progesterone—uterine cancer	0.00597	0.0191	CcSEcCtD
Flavoxate—Vertigo—Medroxyprogesterone Acetate—uterine cancer	0.00591	0.0189	CcSEcCtD
Flavoxate—Palpitations—Medroxyprogesterone Acetate—uterine cancer	0.00581	0.0186	CcSEcCtD
Flavoxate—Tachycardia—Progesterone—uterine cancer	0.00578	0.0185	CcSEcCtD
Flavoxate—Skin disorder—Progesterone—uterine cancer	0.00575	0.0184	CcSEcCtD
Flavoxate—Dry mouth—Medroxyprogesterone Acetate—uterine cancer	0.00547	0.0175	CcSEcCtD
Flavoxate—Confusional state—Medroxyprogesterone Acetate—uterine cancer	0.00541	0.0173	CcSEcCtD
Flavoxate—Somnolence—Progesterone—uterine cancer	0.00526	0.0168	CcSEcCtD
Flavoxate—Tachycardia—Medroxyprogesterone Acetate—uterine cancer	0.00524	0.0167	CcSEcCtD
Flavoxate—Skin disorder—Medroxyprogesterone Acetate—uterine cancer	0.00521	0.0166	CcSEcCtD
Flavoxate—Feeling abnormal—Progesterone—uterine cancer	0.00488	0.0156	CcSEcCtD
Flavoxate—Somnolence—Medroxyprogesterone Acetate—uterine cancer	0.00477	0.0152	CcSEcCtD
Flavoxate—Urticaria—Progesterone—uterine cancer	0.0047	0.015	CcSEcCtD
Flavoxate—Leukopenia—Dactinomycin—uterine cancer	0.00459	0.0147	CcSEcCtD
Flavoxate—Feeling abnormal—Medroxyprogesterone Acetate—uterine cancer	0.00442	0.0141	CcSEcCtD
Flavoxate—Urticaria—Medroxyprogesterone Acetate—uterine cancer	0.00426	0.0136	CcSEcCtD
Flavoxate—Vomiting—Progesterone—uterine cancer	0.00376	0.012	CcSEcCtD
Flavoxate—Headache—Progesterone—uterine cancer	0.00371	0.0118	CcSEcCtD
Flavoxate—Nausea—Progesterone—uterine cancer	0.00352	0.0112	CcSEcCtD
Flavoxate—Feeling abnormal—Dactinomycin—uterine cancer	0.00345	0.011	CcSEcCtD
Flavoxate—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.00341	0.0109	CcSEcCtD
Flavoxate—Headache—Medroxyprogesterone Acetate—uterine cancer	0.00336	0.0107	CcSEcCtD
Flavoxate—Vertigo—Etoposide—uterine cancer	0.00333	0.0107	CcSEcCtD
Flavoxate—Leukopenia—Etoposide—uterine cancer	0.00332	0.0106	CcSEcCtD
Flavoxate—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.00319	0.0102	CcSEcCtD
Flavoxate—Confusional state—Etoposide—uterine cancer	0.00305	0.00976	CcSEcCtD
Flavoxate—Tachycardia—Etoposide—uterine cancer	0.00296	0.00944	CcSEcCtD
Flavoxate—Eosinophilia—Epirubicin—uterine cancer	0.00296	0.00944	CcSEcCtD
Flavoxate—Skin disorder—Etoposide—uterine cancer	0.00294	0.0094	CcSEcCtD
Flavoxate—Eosinophilia—Doxorubicin—uterine cancer	0.00274	0.00874	CcSEcCtD
Flavoxate—Somnolence—Etoposide—uterine cancer	0.00269	0.0086	CcSEcCtD
Flavoxate—Drowsiness—Epirubicin—uterine cancer	0.00266	0.0085	CcSEcCtD
Flavoxate—Vomiting—Dactinomycin—uterine cancer	0.00266	0.0085	CcSEcCtD
Flavoxate—Feeling abnormal—Etoposide—uterine cancer	0.0025	0.00797	CcSEcCtD
Flavoxate—Nausea—Dactinomycin—uterine cancer	0.00249	0.00794	CcSEcCtD
Flavoxate—Drowsiness—Doxorubicin—uterine cancer	0.00246	0.00787	CcSEcCtD
Flavoxate—Urticaria—Etoposide—uterine cancer	0.00241	0.00769	CcSEcCtD
Flavoxate—Tension—Epirubicin—uterine cancer	0.00204	0.00652	CcSEcCtD
Flavoxate—Nervousness—Epirubicin—uterine cancer	0.00202	0.00645	CcSEcCtD
Flavoxate—Vision blurred—Epirubicin—uterine cancer	0.00196	0.00626	CcSEcCtD
Flavoxate—Vomiting—Etoposide—uterine cancer	0.00193	0.00615	CcSEcCtD
Flavoxate—Headache—Etoposide—uterine cancer	0.0019	0.00606	CcSEcCtD
Flavoxate—Tension—Doxorubicin—uterine cancer	0.00189	0.00603	CcSEcCtD
Flavoxate—Nervousness—Doxorubicin—uterine cancer	0.00187	0.00597	CcSEcCtD
Flavoxate—Vertigo—Epirubicin—uterine cancer	0.00187	0.00597	CcSEcCtD
Flavoxate—Leukopenia—Epirubicin—uterine cancer	0.00186	0.00595	CcSEcCtD
Flavoxate—Palpitations—Epirubicin—uterine cancer	0.00184	0.00587	CcSEcCtD
Flavoxate—Vision blurred—Doxorubicin—uterine cancer	0.00181	0.00579	CcSEcCtD
Flavoxate—Nausea—Etoposide—uterine cancer	0.0018	0.00575	CcSEcCtD
Flavoxate—Dry mouth—Epirubicin—uterine cancer	0.00173	0.00553	CcSEcCtD
Flavoxate—Vertigo—Doxorubicin—uterine cancer	0.00173	0.00552	CcSEcCtD
Flavoxate—Leukopenia—Doxorubicin—uterine cancer	0.00172	0.0055	CcSEcCtD
Flavoxate—Confusional state—Epirubicin—uterine cancer	0.00171	0.00547	CcSEcCtD
Flavoxate—Palpitations—Doxorubicin—uterine cancer	0.0017	0.00543	CcSEcCtD
Flavoxate—Tachycardia—Epirubicin—uterine cancer	0.00166	0.00529	CcSEcCtD
Flavoxate—Skin disorder—Epirubicin—uterine cancer	0.00165	0.00527	CcSEcCtD
Flavoxate—Dry mouth—Doxorubicin—uterine cancer	0.0016	0.00512	CcSEcCtD
Flavoxate—Confusional state—Doxorubicin—uterine cancer	0.00158	0.00506	CcSEcCtD
Flavoxate—Tachycardia—Doxorubicin—uterine cancer	0.00153	0.0049	CcSEcCtD
Flavoxate—Skin disorder—Doxorubicin—uterine cancer	0.00153	0.00487	CcSEcCtD
Flavoxate—Somnolence—Epirubicin—uterine cancer	0.00151	0.00482	CcSEcCtD
Flavoxate—Feeling abnormal—Epirubicin—uterine cancer	0.0014	0.00447	CcSEcCtD
Flavoxate—Somnolence—Doxorubicin—uterine cancer	0.0014	0.00446	CcSEcCtD
Flavoxate—Urticaria—Epirubicin—uterine cancer	0.00135	0.00431	CcSEcCtD
Flavoxate—Feeling abnormal—Doxorubicin—uterine cancer	0.00129	0.00414	CcSEcCtD
Flavoxate—Urticaria—Doxorubicin—uterine cancer	0.00125	0.00399	CcSEcCtD
Flavoxate—Vomiting—Epirubicin—uterine cancer	0.00108	0.00345	CcSEcCtD
Flavoxate—Headache—Epirubicin—uterine cancer	0.00106	0.0034	CcSEcCtD
Flavoxate—Nausea—Epirubicin—uterine cancer	0.00101	0.00322	CcSEcCtD
Flavoxate—Vomiting—Doxorubicin—uterine cancer	0.000999	0.00319	CcSEcCtD
Flavoxate—Headache—Doxorubicin—uterine cancer	0.000984	0.00314	CcSEcCtD
Flavoxate—Nausea—Doxorubicin—uterine cancer	0.000933	0.00298	CcSEcCtD
Flavoxate—PDE8B—Signaling Pathways—PTEN—uterine cancer	2.09e-06	0.00131	CbGpPWpGaD
Flavoxate—PDE8A—Signaling Pathways—PTEN—uterine cancer	2.09e-06	0.00131	CbGpPWpGaD
Flavoxate—PDE7B—Signaling Pathways—CXCL8—uterine cancer	2.07e-06	0.0013	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—STK11—uterine cancer	2.07e-06	0.0013	CbGpPWpGaD
Flavoxate—PDE7A—Signaling by GPCR—PIK3CA—uterine cancer	2.07e-06	0.0013	CbGpPWpGaD
Flavoxate—PDE4B—Signaling by GPCR—CCL2—uterine cancer	2.06e-06	0.00129	CbGpPWpGaD
Flavoxate—PDE7B—Signaling by GPCR—HRAS—uterine cancer	2.06e-06	0.00129	CbGpPWpGaD
Flavoxate—CHRM1—Regulation of Actin Cytoskeleton—PIK3CA—uterine cancer	2.06e-06	0.00129	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—IGF1R—uterine cancer	2.05e-06	0.00128	CbGpPWpGaD
Flavoxate—PDE8B—Signaling by GPCR—AKT1—uterine cancer	2.04e-06	0.00128	CbGpPWpGaD
Flavoxate—PDE8A—Signaling by GPCR—AKT1—uterine cancer	2.04e-06	0.00128	CbGpPWpGaD
Flavoxate—PDE4D—GPCR downstream signaling—CXCL8—uterine cancer	2.04e-06	0.00128	CbGpPWpGaD
Flavoxate—PDE7A—Signaling Pathways—ERBB2—uterine cancer	2.03e-06	0.00127	CbGpPWpGaD
Flavoxate—CHRM2—Regulation of Actin Cytoskeleton—PIK3CA—uterine cancer	2.03e-06	0.00127	CbGpPWpGaD
Flavoxate—PDE7B—Signaling Pathways—CDKN1B—uterine cancer	2.02e-06	0.00127	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—CDKN2B—uterine cancer	2.01e-06	0.00126	CbGpPWpGaD
Flavoxate—PDE7B—GPCR downstream signaling—AKT1—uterine cancer	2e-06	0.00125	CbGpPWpGaD
Flavoxate—PDE8B—Signaling Pathways—EP300—uterine cancer	1.99e-06	0.00125	CbGpPWpGaD
Flavoxate—PDE8A—Signaling Pathways—EP300—uterine cancer	1.99e-06	0.00125	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—IGF1R—uterine cancer	1.95e-06	0.00122	CbGpPWpGaD
Flavoxate—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—uterine cancer	1.94e-06	0.00122	CbGpPWpGaD
Flavoxate—PDE4A—GPCR downstream signaling—CXCL8—uterine cancer	1.94e-06	0.00122	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—SOCS3—uterine cancer	1.94e-06	0.00122	CbGpPWpGaD
Flavoxate—PDE7A—Signaling Pathways—CXCL8—uterine cancer	1.93e-06	0.00121	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—SMAD3—uterine cancer	1.92e-06	0.00121	CbGpPWpGaD
Flavoxate—PDE7A—Signaling by GPCR—HRAS—uterine cancer	1.91e-06	0.0012	CbGpPWpGaD
Flavoxate—PDE7B—Signaling Pathways—CTNNB1—uterine cancer	1.91e-06	0.0012	CbGpPWpGaD
Flavoxate—PDE8B—Signaling Pathways—VEGFA—uterine cancer	1.89e-06	0.00118	CbGpPWpGaD
Flavoxate—PDE8A—Signaling Pathways—VEGFA—uterine cancer	1.89e-06	0.00118	CbGpPWpGaD
Flavoxate—PDE7A—Signaling Pathways—CDKN1B—uterine cancer	1.88e-06	0.00118	CbGpPWpGaD
Flavoxate—PDE8B—Signaling Pathways—NRAS—uterine cancer	1.87e-06	0.00117	CbGpPWpGaD
Flavoxate—PDE8A—Signaling Pathways—NRAS—uterine cancer	1.87e-06	0.00117	CbGpPWpGaD
Flavoxate—PDE7B—Signaling Pathways—PTEN—uterine cancer	1.86e-06	0.00117	CbGpPWpGaD
Flavoxate—PDE7A—GPCR downstream signaling—AKT1—uterine cancer	1.86e-06	0.00117	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—CDKN2B—uterine cancer	1.86e-06	0.00116	CbGpPWpGaD
Flavoxate—PDE4D—Signaling by GPCR—CXCL8—uterine cancer	1.85e-06	0.00116	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—FGFR2—uterine cancer	1.84e-06	0.00115	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—SMAD3—uterine cancer	1.83e-06	0.00115	CbGpPWpGaD
Flavoxate—PDE7B—Signaling by GPCR—AKT1—uterine cancer	1.82e-06	0.00114	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—ESR1—uterine cancer	1.8e-06	0.00113	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—IGF1R—uterine cancer	1.8e-06	0.00113	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—RNF43—uterine cancer	1.8e-06	0.00113	CbGpPWpGaD
Flavoxate—PDE4B—GPCR downstream signaling—CXCL8—uterine cancer	1.79e-06	0.00112	CbGpPWpGaD
Flavoxate—CHRM1—Class A/1 (Rhodopsin-like receptors)—CXCL8—uterine cancer	1.79e-06	0.00112	CbGpPWpGaD
Flavoxate—PDE7A—Signaling Pathways—CTNNB1—uterine cancer	1.78e-06	0.00111	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—RNF43—uterine cancer	1.78e-06	0.00111	CbGpPWpGaD
Flavoxate—PDE7B—Signaling Pathways—EP300—uterine cancer	1.78e-06	0.00111	CbGpPWpGaD
Flavoxate—CHRM2—Class A/1 (Rhodopsin-like receptors)—CXCL8—uterine cancer	1.77e-06	0.00111	CbGpPWpGaD
Flavoxate—PDE4A—Signaling by GPCR—CXCL8—uterine cancer	1.76e-06	0.0011	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—FGFR2—uterine cancer	1.75e-06	0.00109	CbGpPWpGaD
Flavoxate—PDE7A—Signaling Pathways—PTEN—uterine cancer	1.73e-06	0.00109	CbGpPWpGaD
Flavoxate—CHRM1—GPCR ligand binding—CCL2—uterine cancer	1.72e-06	0.00108	CbGpPWpGaD
Flavoxate—CHRM1—G alpha (q) signalling events—PIK3CA—uterine cancer	1.72e-06	0.00108	CbGpPWpGaD
Flavoxate—PDE4C—Signaling by GPCR—NRAS—uterine cancer	1.71e-06	0.00107	CbGpPWpGaD
Flavoxate—CHRM2—GPCR ligand binding—CCL2—uterine cancer	1.7e-06	0.00107	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—SMAD3—uterine cancer	1.69e-06	0.00106	CbGpPWpGaD
Flavoxate—PDE7A—Signaling by GPCR—AKT1—uterine cancer	1.69e-06	0.00106	CbGpPWpGaD
Flavoxate—PDE7B—Signaling Pathways—VEGFA—uterine cancer	1.68e-06	0.00105	CbGpPWpGaD
Flavoxate—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—uterine cancer	1.67e-06	0.00105	CbGpPWpGaD
Flavoxate—PDE7B—Signaling Pathways—NRAS—uterine cancer	1.66e-06	0.00104	CbGpPWpGaD
Flavoxate—PDE7A—Signaling Pathways—EP300—uterine cancer	1.65e-06	0.00104	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—INHBA—uterine cancer	1.65e-06	0.00103	CbGpPWpGaD
Flavoxate—PDE4B—Signaling by GPCR—CXCL8—uterine cancer	1.63e-06	0.00102	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—INHBA—uterine cancer	1.63e-06	0.00102	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—FGFR2—uterine cancer	1.62e-06	0.00101	CbGpPWpGaD
Flavoxate—PDE8A—Signaling Pathways—KRAS—uterine cancer	1.61e-06	0.00101	CbGpPWpGaD
Flavoxate—PDE8B—Signaling Pathways—KRAS—uterine cancer	1.61e-06	0.00101	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—CCL2—uterine cancer	1.59e-06	0.000995	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—ESR1—uterine cancer	1.57e-06	0.000984	CbGpPWpGaD
Flavoxate—CHRM1—Circadian rythm related genes—TP53—uterine cancer	1.57e-06	0.000982	CbGpPWpGaD
Flavoxate—PDE7A—Signaling Pathways—VEGFA—uterine cancer	1.56e-06	0.000981	CbGpPWpGaD
Flavoxate—PDE7A—Signaling Pathways—NRAS—uterine cancer	1.55e-06	0.000969	CbGpPWpGaD
Flavoxate—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—uterine cancer	1.53e-06	0.000962	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—ESR1—uterine cancer	1.49e-06	0.000937	CbGpPWpGaD
Flavoxate—PDE4C—GPCR downstream signaling—PIK3CA—uterine cancer	1.48e-06	0.000931	CbGpPWpGaD
Flavoxate—PDE4D—Signaling by GPCR—NRAS—uterine cancer	1.48e-06	0.00093	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—AKR1C1—uterine cancer	1.48e-06	0.000929	CbGpPWpGaD
Flavoxate—PDE8B—Signaling Pathways—PIK3CA—uterine cancer	1.47e-06	0.000924	CbGpPWpGaD
Flavoxate—PDE8A—Signaling Pathways—PIK3CA—uterine cancer	1.47e-06	0.000924	CbGpPWpGaD
Flavoxate—PDE4C—Signaling by GPCR—KRAS—uterine cancer	1.47e-06	0.00092	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—AKR1C1—uterine cancer	1.46e-06	0.000917	CbGpPWpGaD
Flavoxate—PDE7B—Signaling Pathways—KRAS—uterine cancer	1.43e-06	0.000897	CbGpPWpGaD
Flavoxate—PDE8A—Signaling Pathways—TP53—uterine cancer	1.43e-06	0.000894	CbGpPWpGaD
Flavoxate—PDE8B—Signaling Pathways—TP53—uterine cancer	1.43e-06	0.000894	CbGpPWpGaD
Flavoxate—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—uterine cancer	1.42e-06	0.00089	CbGpPWpGaD
Flavoxate—PDE4A—Signaling by GPCR—NRAS—uterine cancer	1.41e-06	0.000885	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—ESR1—uterine cancer	1.38e-06	0.000867	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—CCL2—uterine cancer	1.38e-06	0.000866	CbGpPWpGaD
Flavoxate—PDE8A—Signaling Pathways—HRAS—uterine cancer	1.36e-06	0.000855	CbGpPWpGaD
Flavoxate—PDE8B—Signaling Pathways—HRAS—uterine cancer	1.36e-06	0.000855	CbGpPWpGaD
Flavoxate—CHRM1—GPCR ligand binding—CXCL8—uterine cancer	1.36e-06	0.000855	CbGpPWpGaD
Flavoxate—PDE4C—Signaling by GPCR—PIK3CA—uterine cancer	1.35e-06	0.000845	CbGpPWpGaD
Flavoxate—CHRM2—GPCR ligand binding—CXCL8—uterine cancer	1.35e-06	0.000844	CbGpPWpGaD
Flavoxate—PDE7A—Signaling Pathways—KRAS—uterine cancer	1.33e-06	0.000834	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—ERBB2—uterine cancer	1.32e-06	0.00083	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—CCL2—uterine cancer	1.32e-06	0.000825	CbGpPWpGaD
Flavoxate—PDE7B—Signaling Pathways—PIK3CA—uterine cancer	1.31e-06	0.000824	CbGpPWpGaD
Flavoxate—PDE4B—Signaling by GPCR—NRAS—uterine cancer	1.31e-06	0.000819	CbGpPWpGaD
Flavoxate—PDE4D—GPCR downstream signaling—PIK3CA—uterine cancer	1.29e-06	0.00081	CbGpPWpGaD
Flavoxate—PDE4D—Signaling by GPCR—KRAS—uterine cancer	1.28e-06	0.000801	CbGpPWpGaD
Flavoxate—PDE7B—Signaling Pathways—TP53—uterine cancer	1.27e-06	0.000797	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—CXCL8—uterine cancer	1.26e-06	0.000787	CbGpPWpGaD
Flavoxate—PDE4C—Signaling by GPCR—HRAS—uterine cancer	1.25e-06	0.000782	CbGpPWpGaD
Flavoxate—PDE4A—GPCR downstream signaling—PIK3CA—uterine cancer	1.23e-06	0.000771	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—CDKN1B—uterine cancer	1.23e-06	0.000768	CbGpPWpGaD
Flavoxate—PDE7A—Signaling Pathways—PIK3CA—uterine cancer	1.22e-06	0.000766	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—CCL2—uterine cancer	1.22e-06	0.000763	CbGpPWpGaD
Flavoxate—PDE7B—Signaling Pathways—HRAS—uterine cancer	1.22e-06	0.000762	CbGpPWpGaD
Flavoxate—PDE4A—Signaling by GPCR—KRAS—uterine cancer	1.22e-06	0.000762	CbGpPWpGaD
Flavoxate—PDE4C—GPCR downstream signaling—AKT1—uterine cancer	1.21e-06	0.00076	CbGpPWpGaD
Flavoxate—PDE8A—Signaling Pathways—AKT1—uterine cancer	1.2e-06	0.000755	CbGpPWpGaD
Flavoxate—PDE8B—Signaling Pathways—AKT1—uterine cancer	1.2e-06	0.000755	CbGpPWpGaD
Flavoxate—PDE7A—Signaling Pathways—TP53—uterine cancer	1.18e-06	0.000741	CbGpPWpGaD
Flavoxate—PDE4D—Signaling by GPCR—PIK3CA—uterine cancer	1.17e-06	0.000736	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—CTNNB1—uterine cancer	1.16e-06	0.000726	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—ERBB2—uterine cancer	1.15e-06	0.000722	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—AKR1C3—uterine cancer	1.14e-06	0.000715	CbGpPWpGaD
Flavoxate—PDE4B—GPCR downstream signaling—PIK3CA—uterine cancer	1.14e-06	0.000713	CbGpPWpGaD
Flavoxate—PDE7A—Signaling Pathways—HRAS—uterine cancer	1.13e-06	0.000709	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—PTEN—uterine cancer	1.13e-06	0.000708	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—AKR1C3—uterine cancer	1.13e-06	0.000706	CbGpPWpGaD
Flavoxate—PDE4B—Signaling by GPCR—KRAS—uterine cancer	1.13e-06	0.000705	CbGpPWpGaD
Flavoxate—PDE4A—Signaling by GPCR—PIK3CA—uterine cancer	1.12e-06	0.0007	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—PGR—uterine cancer	1.11e-06	0.000697	CbGpPWpGaD
Flavoxate—PDE4C—Signaling by GPCR—AKT1—uterine cancer	1.1e-06	0.00069	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—PGR—uterine cancer	1.1e-06	0.000688	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—ERBB2—uterine cancer	1.1e-06	0.000688	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—CXCL8—uterine cancer	1.09e-06	0.000685	CbGpPWpGaD
Flavoxate—PDE4D—Signaling by GPCR—HRAS—uterine cancer	1.09e-06	0.000681	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—EP300—uterine cancer	1.08e-06	0.000675	CbGpPWpGaD
Flavoxate—PDE7B—Signaling Pathways—AKT1—uterine cancer	1.07e-06	0.000673	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—CDKN1B—uterine cancer	1.07e-06	0.000669	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—YWHAE—uterine cancer	1.06e-06	0.000665	CbGpPWpGaD
Flavoxate—PDE4D—GPCR downstream signaling—AKT1—uterine cancer	1.06e-06	0.000662	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—YWHAE—uterine cancer	1.05e-06	0.000657	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—CXCL8—uterine cancer	1.04e-06	0.000652	CbGpPWpGaD
Flavoxate—PDE4B—Signaling by GPCR—PIK3CA—uterine cancer	1.03e-06	0.000648	CbGpPWpGaD
Flavoxate—PDE4A—Signaling by GPCR—HRAS—uterine cancer	1.03e-06	0.000648	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—VEGFA—uterine cancer	1.02e-06	0.000639	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—FBXW7—uterine cancer	1.02e-06	0.000638	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—CDKN1B—uterine cancer	1.02e-06	0.000637	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—ERBB2—uterine cancer	1.02e-06	0.000636	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—CTNNB1—uterine cancer	1.01e-06	0.000632	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—NRAS—uterine cancer	1.01e-06	0.000631	CbGpPWpGaD
Flavoxate—PDE4A—GPCR downstream signaling—AKT1—uterine cancer	1e-06	0.00063	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—FBXW7—uterine cancer	1e-06	0.000629	CbGpPWpGaD
Flavoxate—PDE7A—Signaling Pathways—AKT1—uterine cancer	9.98e-07	0.000626	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—PTEN—uterine cancer	9.83e-07	0.000616	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—CXCL8—uterine cancer	9.63e-07	0.000603	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—CTNNB1—uterine cancer	9.6e-07	0.000602	CbGpPWpGaD
Flavoxate—PDE4D—Signaling by GPCR—AKT1—uterine cancer	9.59e-07	0.000601	CbGpPWpGaD
Flavoxate—PDE4B—Signaling by GPCR—HRAS—uterine cancer	9.56e-07	0.000599	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—CDKN1B—uterine cancer	9.4e-07	0.000589	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—EP300—uterine cancer	9.37e-07	0.000587	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—PTEN—uterine cancer	9.35e-07	0.000586	CbGpPWpGaD
Flavoxate—PDE4B—GPCR downstream signaling—AKT1—uterine cancer	9.3e-07	0.000583	CbGpPWpGaD
Flavoxate—PDE4A—Signaling by GPCR—AKT1—uterine cancer	9.13e-07	0.000572	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—EP300—uterine cancer	8.92e-07	0.000559	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—STK11—uterine cancer	8.89e-07	0.000557	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—CTNNB1—uterine cancer	8.88e-07	0.000557	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—VEGFA—uterine cancer	8.88e-07	0.000556	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—CCL2—uterine cancer	8.85e-07	0.000555	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—STK11—uterine cancer	8.78e-07	0.00055	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—NRAS—uterine cancer	8.77e-07	0.00055	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—CCL2—uterine cancer	8.74e-07	0.000548	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—KRAS—uterine cancer	8.67e-07	0.000543	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—PTEN—uterine cancer	8.66e-07	0.000542	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—VEGFA—uterine cancer	8.45e-07	0.00053	CbGpPWpGaD
Flavoxate—PDE4B—Signaling by GPCR—AKT1—uterine cancer	8.44e-07	0.000529	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—NRAS—uterine cancer	8.35e-07	0.000523	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—SOCS3—uterine cancer	8.33e-07	0.000522	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—EP300—uterine cancer	8.25e-07	0.000517	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—SOCS3—uterine cancer	8.22e-07	0.000515	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—CDKN2B—uterine cancer	7.97e-07	0.0005	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—PIK3CA—uterine cancer	7.96e-07	0.000499	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—CDKN2B—uterine cancer	7.87e-07	0.000493	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—VEGFA—uterine cancer	7.82e-07	0.00049	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—IGF1R—uterine cancer	7.74e-07	0.000485	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—NRAS—uterine cancer	7.72e-07	0.000484	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—CXCL8—uterine cancer	7.71e-07	0.000483	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—TP53—uterine cancer	7.7e-07	0.000483	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—IGF1R—uterine cancer	7.64e-07	0.000479	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—CXCL8—uterine cancer	7.61e-07	0.000477	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—KRAS—uterine cancer	7.55e-07	0.000473	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—HRAS—uterine cancer	7.37e-07	0.000462	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—SMAD3—uterine cancer	7.28e-07	0.000456	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—SMAD3—uterine cancer	7.18e-07	0.00045	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—KRAS—uterine cancer	7.18e-07	0.00045	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—CXCL8—uterine cancer	7e-07	0.000439	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—FGFR2—uterine cancer	6.94e-07	0.000435	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—PIK3CA—uterine cancer	6.93e-07	0.000435	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—CXCL8—uterine cancer	6.91e-07	0.000433	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—FGFR2—uterine cancer	6.85e-07	0.00043	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—TP53—uterine cancer	6.71e-07	0.00042	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—KRAS—uterine cancer	6.65e-07	0.000417	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—PIK3CA—uterine cancer	6.6e-07	0.000414	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—AKT1—uterine cancer	6.51e-07	0.000408	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—HRAS—uterine cancer	6.41e-07	0.000402	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—TP53—uterine cancer	6.38e-07	0.0004	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—PIK3CA—uterine cancer	6.11e-07	0.000383	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—HRAS—uterine cancer	6.11e-07	0.000383	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—ESR1—uterine cancer	5.94e-07	0.000372	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—TP53—uterine cancer	5.91e-07	0.00037	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—ESR1—uterine cancer	5.86e-07	0.000367	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—AKT1—uterine cancer	5.66e-07	0.000355	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—HRAS—uterine cancer	5.65e-07	0.000354	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—NRAS—uterine cancer	5.61e-07	0.000352	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—NRAS—uterine cancer	5.54e-07	0.000347	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—AKT1—uterine cancer	5.39e-07	0.000338	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—CCL2—uterine cancer	5.23e-07	0.000328	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—CCL2—uterine cancer	5.16e-07	0.000324	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—AKT1—uterine cancer	4.99e-07	0.000313	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—PIK3CA—uterine cancer	4.89e-07	0.000306	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—KRAS—uterine cancer	4.83e-07	0.000303	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—PIK3CA—uterine cancer	4.83e-07	0.000302	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—KRAS—uterine cancer	4.77e-07	0.000299	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—PIK3CA—uterine cancer	4.44e-07	0.000278	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—PIK3CA—uterine cancer	4.38e-07	0.000275	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—ERBB2—uterine cancer	4.36e-07	0.000273	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—ERBB2—uterine cancer	4.3e-07	0.00027	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—CXCL8—uterine cancer	4.13e-07	0.000259	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—HRAS—uterine cancer	4.11e-07	0.000257	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—CXCL8—uterine cancer	4.08e-07	0.000256	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—HRAS—uterine cancer	4.05e-07	0.000254	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—CDKN1B—uterine cancer	4.04e-07	0.000253	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—AKT1—uterine cancer	3.99e-07	0.00025	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—CDKN1B—uterine cancer	3.99e-07	0.00025	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—AKT1—uterine cancer	3.94e-07	0.000247	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—CTNNB1—uterine cancer	3.81e-07	0.000239	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—CTNNB1—uterine cancer	3.77e-07	0.000236	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—PTEN—uterine cancer	3.72e-07	0.000233	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—PTEN—uterine cancer	3.67e-07	0.00023	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—AKT1—uterine cancer	3.63e-07	0.000227	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—AKT1—uterine cancer	3.58e-07	0.000224	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—EP300—uterine cancer	3.55e-07	0.000222	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—EP300—uterine cancer	3.5e-07	0.000219	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—VEGFA—uterine cancer	3.36e-07	0.00021	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—NRAS—uterine cancer	3.32e-07	0.000208	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—VEGFA—uterine cancer	3.31e-07	0.000208	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—NRAS—uterine cancer	3.27e-07	0.000205	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—KRAS—uterine cancer	2.85e-07	0.000179	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—KRAS—uterine cancer	2.82e-07	0.000177	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—PIK3CA—uterine cancer	2.62e-07	0.000164	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—PIK3CA—uterine cancer	2.59e-07	0.000162	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—TP53—uterine cancer	2.54e-07	0.000159	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—TP53—uterine cancer	2.5e-07	0.000157	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—HRAS—uterine cancer	2.43e-07	0.000152	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—HRAS—uterine cancer	2.4e-07	0.00015	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—AKT1—uterine cancer	2.14e-07	0.000134	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—AKT1—uterine cancer	2.11e-07	0.000133	CbGpPWpGaD
